Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Pharmaceutical Research|December 30, 2009
Population in vitro-in vivo correlation model for pramipexole slow-release oral formulationsElena Soto, Sebastian Haertter, Michael Koenen-Bergmann, et al.
European Journal of Clinical Pharmacology|April 14, 2007
Tadalafil population pharmacokinetics in patients with erectile dysfunctionIñaki F Trocóniz, Christiane Tillmann, Alexander Staab, et al.
Biopharmaceutics & Drug Disposition|September 23, 2009
Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype ratsSilke Retlich, Barbara Withopf, Andreas Greischel, et al.
Cancer Chemotherapy and Pharmacology|April 26, 2011
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitorElena Soto, Alexander Staab, Christiane Doege, et al.
Clinical Pharmacokinetics|March 27, 2013
Pharmacometric characterization of dabigatran hemodialysisKarl-Heinz Liesenfeld, Alexander Staab, Sebastian Härtter, et al.
Pharmaceutical Research|June 26, 2007
Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel BlockerGabriele Fliss, Alexander Staab, Christiane Tillmann, et al.
Clinical Pharmacokinetics|August 27, 2009
A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicamThorsten Lehr, Alexander Staab, Christiane Tillmann, et al.
British Journal of Clinical Pharmacology|September 9, 2015
Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approachJens Markus Borghardt, Benjamin Weber, Alexander Staab, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 21, 2003
Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single dosesAlexander Staab, Barbara S Schug, Véronique Larsimont, et al.
Cancer Chemotherapy and Pharmacology|January 12, 2010
Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical developmentElena Soto, Alexander Staab, Christiane Tillmann, et al.
Pageof 4